AstraZeneca to provide free prescription drugs and expand to more facilities
WILMINGTON, Del. AstraZeneca will provide its prescription drugs free of charge to low-income patients, according to Wednesday’s reports.
AstraZeneca said it plans to add 150 more health care facilities to its program, bringing the number participating to 270 by the end of 2008, though the new locations are to be determined, said Karissa Laur, who directs the company’s patient assistance programs.
Patients who don’t have prescription drug coverage and whose household income is $30,000 or less for an individual, or $60,000 or less for a family of four, are eligible for free AstraZeneca prescription drugs under the program. The objective is to better harmonize patient care and access to needed medications by providing prescription drugs at the place where many uninsured people receive their health care.
AstraZeneca, through its various patient assistance programs, said it saved $407 million last year for more than 530,000 patients in the U.S. and Puerto Rico.
Providing prescription drugs directly to health care facilities is beneficial because it can “expedite the process and get drugs to patients faster,” said Laurie Felland, a health researcher with the Washington D.C-based Center for Studying Health System Change.
Health care providers turn to the pharmaceutical companies as a major source of the medications they need to treat their patients, most of whom lack prescription drug coverage. Last year, approximately 47 million Americans lacked health insurance, up 2.2 million from 2005.
Mylan announces new appointments
PITTSBURGH Upon the news of the acquisition involving Merck’s KGaA generic business by Mylan, Mylan released a group of statements regarding new appointments to positions within the company worldwide.
The appointments include: Harry Korman as President, North America; Rajiv Malik as Executive Vice President in charge or Global Technical Operations; Carolyn Myers, Ph.D. President-elect of Dey; Christy Taylor as Chief Operating Officer of Dey; Didier Barret as President of Europe, Middle East, and Africa; Heather Bresch as Chief Operating Officer; and John Montgomery as President, Asia Pacific.
Mylan acquired Merck’s generics for $6.8 billion in cash.
FDA approves Afluria flu vaccine
AUSTRALIA The Food and Drug Administration has approved CSL’s flu vaccine Afluria, according to The Australian.
The company expects to ship two million doses as part of its first shipment to the U.S. between mid-December and early February. The company expects to increase its export to 20 million doses over the next four years.
“We’ve entered the US market quite late, but over the next few years we hope to increase our export of flu vaccine to the US to 20 million doses,” CSL’s Dr Rachel David said.